MangoRx Acquires Patent Portfolio For Total Of $20M Through Issuance Of 980K Of 6% Series C Convertible Preferred Shares
MangoRx Acquires Patent Portfolio For Total Of $20M Through Issuance Of 980K Of 6% Series C Convertible Preferred Shares
Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair
Mangoceuticals, Inc.（納斯達克股票代碼：MGRX）（“MangorX” 或 “公司”），一家專注於開發、營銷和銷售勃起功能障礙（ED）、頭髮領域的各種男性健康和保健產品的公司
Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth and hormone replacement therapies is excited to announce that it has acquired a global patent portfolio for a pioneering oral solution and application aimed to combat and prevent a spectrum of infections, including the common cold, respiratory diseases, and orally transmitted diseases such as human papillomavirus (HPV) (the "Patent Portfolio") from Intramont Technologies, Inc. ("Intramont"), pursuant to a Patent Purchase Agreement ("PPA").
Mangoceuticals, Inc.（納斯達克股票代碼：MGRX）（“MangorX” 或 “公司”）是一家專注於開發、營銷和銷售勃起功能障礙（ED）、頭髮生長和激素替代療法領域各種男士健康和保健產品的公司，很高興地宣佈，它已獲得一項旨在對抗和預防一系列感染的開創性口服溶液和應用的全球專利組合，包括普通感冒、呼吸系統疾病和人乳頭瘤病毒（HPV）等口腔傳播疾病（“專利組合”）根據專利購買協議（“PPA”），來自英特蒙特科技公司（“Intramont”）。